SSA
IBER.U

Schonfeld Strategic Advisors’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-135,445
Closed -$1.36M – 2596
2021
Q2 		$1.36M Sell
135,445
-14,555
-10% -$146K 0.01% 841
2021
Q1 		$1.48M Buy
+150,000
New +$1.5M 0.02% 759

Other funds holding IBER.U

HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schonfeld Strategic Advisors's IBER.U Position: Q3 2021 in Review

Schonfeld Strategic Advisors sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q3 2021, closing a stake of 135,445 shares — an estimated $1.36M sold.

Schonfeld Strategic Advisors first reported a position in IBER.U in Q1 2021 and held it in 2 quarters. The position peaked at $1.48M in Q1 2021. 27 funds tracked by Wall St. Rank hold IBER.U as of Q3 2021.

  • Schonfeld Strategic Advisors reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q3 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 135,445 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q3 2021, an estimated $1.36M.
  • Schonfeld Strategic Advisors first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $1.48M in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q3 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.